Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Daiichi Sankyo looks forward to continuing to work with the FDA to bring this potential first-in-class B7-H3 directed DXd antibody drug conjugate to patients as quickly as possible

  60% confidence

• The FDA's granting of Priority Review for ifinatamab deruxtecan marks a significant milestone in our effort to provide new and innovative treatment options for patients with extensive-stage small cell lung cancer

  60% confidence

Cited in these Via News reports

• FDA Fast-Tracks Lung Cancer Drug as Biotech Sector Logs $430M in Deals →
• Gilead Buys Ouro Medicines, Gives Spin-Off $500M to Build Global Inflammation Pipeline →
• Gilead and Europe's Lakefront Close $500M Ouro Deal in Cross-Atlantic Biotech Push →